← Eichor
Condition: Tyrosine Kinase Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Tyrosine Kinase Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP
Phase 2 · 24 location(s) · Novartis Pharmaceuticals · NCT07354074Efficiency of Imatinib Treatment After 10 Years of Treatment in Patients With Gastrointestinal Stromal Tumours (GIST) (G
Phase 2 · 13 location(s) · Centre Leon Berard · NCT05009927An Observational Study in Participants With Indolent Systemic Mastocytosis (ISM)
Phase N/A · 1 location(s) · Blueprint Medicines Corporation · NCT07264959XL092 and Cemiplimab in BRAF WT Thyroid Cancer
Phase 1 · 2 location(s) · UNC Lineberger Comprehensive Cancer Center · NCT06902376ELVN-001 for the Treatment of Chronic Myeloid Leukemia With and Without T315I Mutation in Japanese Participants
Phase 1 · 4 location(s) · Enliven Therapeutics · NCT06787144Response of Bony Metastasis to Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancers With Actionable Driver Mutation
Phase N/A · 2 location(s) · University of Colorado, Denver · NCT03958565Glutamine Plus L. Reuteri Prevents TKI Therapy-diarrhea in Patients With NSCLC
Phase 3 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05852990Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harbor
Phase 3 · 199 location(s) · Boehringer Ingelheim · NCT07195695Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Li
Phase 3 · 78 location(s) · ArriVent BioPharma, Inc. · NCT07185997Clonal Dynamics of Chronic Lymphocytic Leukaemia Treated With Pirtobrutinib After Previous Treatment With Zanubrutinib
Phase 2 · 3 location(s) · Peter MacCallum Cancer Centre, Australia · NCT06812715Metformin Plus Tyrosine Kinase Inhibitors for Treatment of Patients With Non-small Cell Lung Cancer With EGFR Mutations
Phase 3 · 1 location(s) · Instituto Nacional de Cancerologia de Mexico · NCT05445791ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIs
Phase 2 · 1 location(s) · Fudan University · NCT06775743Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR
Phase 2 · 1 location(s) · Peng Zhang · NCT06755684ProSpecTive sAmpling in dRiver muTation Pulmonary Oncology Patients on Tyrosine Kinase Inhibitors (START-TKI)
Phase N/A · 1 location(s) · Erasmus Medical Center · NCT05221372A Study of Almonertinib Combined With Palbociclib in Patients With Advanced Solid Tumors Harboring KRAS Mutations
Phase 1/Phase 2 · 1 location(s) · Sun Yat-sen University · NCT06947811Trilaciclib in Patients Receiving Sacituzumab Tirumotecan for EGFR-mutated, Advanced Non-Small Cell Lung Cancer (NSCLC)
Phase 2 · 1 location(s) · The First Affiliated Hospital of Xiamen University · NCT06992739DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
Phase 2/Phase 3 · 17 location(s) · Cancer Research UK · NCT06988475Efficacy of Platinum-based Chemotherapy Plus Immune Checkpoint Inhibitors for EGFR/ALK/ROS1 Mutant Lung Cancer
Phase 2 · 1 location(s) · Hunan Province Tumor Hospital · NCT05284539LIVInG With chrONic Cancer TrEatments (LONGEVITI) Study
Phase N/A · 1 location(s) · University of Alberta · NCT05645510Radiation Prior to TKI to Delay Progression in Advanced Driver-Mutated Non-small Cell Lung Cancers (RadiaNCe Lung X)
Phase 2 · 1 location(s) · Medical College of Wisconsin · NCT06305715A Study of Stereotactic Radiosurgery (SRS) and Standard Treatment in People With Lung Cancer That Has Spread to the Brai
Phase 2 · 8 location(s) · Memorial Sloan Kettering Cancer Center · NCT06741085A Non-Interventional Study in Participants With Indolent Systemic Mastocytosis (ISM) in Germany
Phase N/A · 8 location(s) · Blueprint Medicines Corporation · NCT07255638Study of Iadademstat and Gilteritinib in Patients With R/R AML With FMS-like Tyrosine Kinase Mutation (FLT3 Mut+)
Phase 1 · 13 location(s) · Oryzon Genomics S.A. · NCT05546580DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Canc
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05770037Neoadjuvant Immunotherapy in Rare Mutations Localized NSCLC
Phase 2 · 1 location(s) · Guangdong Provincial People's Hospital · NCT05800340Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are Resistant, Intolerant or Ineligi
Phase 2 · 6 location(s) · Novartis Pharmaceuticals · NCT06514534CAnadian CAncers With Rare Molecular Alterations (CARMA) - Basket Real-world Observational Study (BROS)
Phase N/A · 27 location(s) · University Health Network, Toronto · NCT04151342A Study of VRN110755 in Patients With EGFR-Mutant Non-Small Cell Lung Cancer
Phase 1/Phase 2 · 29 location(s) · Voronoi, Inc · NCT07699328Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis
Phase N/A · 1 location(s) · National Cancer Institute (NCI) · NCT04557969DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using
Phase 2/Phase 3 · 27 location(s) · Cancer Research UK · NCT05722886
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.